Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. A Nigerian…
Seafood towers, endless Honey Deuces and $100,000 suites: How the US Open lures in high-rollers and celebrities
By Press Room
6 Mins read
In the waning weeks of summer, the hottest spot for celebrities to be seen in New York isn’t the beaches of Montauk…
Alibaba: Restructuring And Investment Efforts - Bullish Support Is Growing (NYSE:BABA)
By Press Room
4 Mins read
BABA’s Reversal May Already Be Here We previously covered Alibaba Group Holding Limited (NYSE:NYSE:BABA) in April 2024, discussing the stock’s underperformance despite…
Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. German authorities…
After a grueling two years of high inflation and elevated interest rates, Americans are finally set for some relief: Federal Reserve Chair…
Shares of Snowflake (NYSE:SNOW) fell sharply after the cloud-focused software company reported earnings for its second fiscal quarter, which on one hand…
Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. One of…
Walmart is hoping Burger King will give its subscription program a whopper of an advantage over Amazon. The retailer is partnering with…
Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective (NASDAQ:RARE)
By Press Room
6 Mins read
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) develops innovative therapies for rare and ultra-rare genetic diseases. Its commercial portfolio includes Crysvita, Mepsevii, Dojolvi, and Evkeeza,…
Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The manufacturer…